Dashboard
Manage Tickers

JNJJOHNSON & JOHNSON

NYSE jnj.com


$ 154.35 $ 1.68 (1.1 %)    

Thursday, 16-May-2024 15:59:46 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 451.64 $ -1.83 (-0.4 %)
DIA $ 399.14 $ -0.07 (-0.02 %)
SPY $ 528.49 $ -1.29 (-0.24 %)
TLT $ 92.06 $ -0.04 (-0.04 %)
GLD $ 220.06 $ -0.86 (-0.39 %)
$ 154.28
$ 152.94
$ 0.00 x 0
$ 0.00 x 0
$ 152.38 - $ 154.38
$ 142.71 - $ 172.01
5,547,955
na
374.92B
$ 0.49
$ 9.74
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-01-2024 03-31-2024 10-Q
2 02-16-2024 12-31-2023 10-K
3 10-27-2023 10-01-2023 10-Q
4 10-27-2023 10-01-2023 10-Q
5 07-31-2023 07-02-2023 10-Q
6 04-28-2023 04-02-2023 10-Q
7 02-16-2023 01-01-2023 10-K
8 10-27-2022 10-02-2022 10-Q
9 07-29-2022 07-03-2022 10-Q
10 04-29-2022 04-03-2022 10-Q
11 02-17-2022 01-02-2022 10-K
12 10-29-2021 10-03-2021 10-Q
13 07-29-2021 07-04-2021 10-Q
14 04-30-2021 04-04-2021 10-Q
15 02-22-2021 01-03-2021 10-K
16 10-23-2020 09-27-2020 10-Q
17 07-24-2020 06-28-2020 10-Q
18 04-29-2020 03-29-2020 10-Q
19 02-18-2020 12-29-2019 10-K
20 10-28-2019 09-29-2019 10-Q
21 07-29-2019 06-30-2019 10-Q
22 05-01-2019 03-31-2019 10-Q
23 02-20-2019 12-30-2018 10-K
24 10-31-2018 09-30-2018 10-Q
25 08-02-2018 07-01-2018 10-Q
26 05-01-2018 04-01-2018 10-Q
27 02-21-2018 12-31-2017 10-K
28 11-02-2017 10-01-2017 10-Q
29 08-03-2017 07-02-2017 10-Q
30 05-08-2017 04-02-2017 10-Q
31 02-27-2017 01-01-2017 10-K
32 11-04-2016 10-02-2016 10-Q
33 08-04-2016 07-03-2016 10-Q
34 05-10-2016 04-03-2016 10-Q
35 02-24-2016 01-03-2016 10-K
36 10-30-2015 09-27-2015 10-Q
37 07-31-2015 06-28-2015 10-Q
38 05-01-2015 03-29-2015 10-Q
39 02-24-2015 12-28-2014 10-K
40 10-30-2014 09-28-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

rbc-capital-reiterates-outperform-on-johnson--johnson-maintains-175-price-target
RBC Capital Reiterates Outperform on Johns...
05/16/2024 16:45:03

RBC Capital analyst Shagun Singh reiterates Johnson & Johnson (NYSE:JNJ) with a Outperform and maintains $175 price target.

johnson--johnson-to-acquire-early-stage-eczema-treatment-developer-proteologix-for-850m
Johnson & Johnson To Acquire Early-Stage E...
05/16/2024 16:35:58

Johnson & Johnson acquires Proteologix for $850 million, expanding its bispecific antibody portfolio for immune-mediated di...

pfizer-astrazeneca-sanofi-and-mainz-biomed-to-uplevel-europes-pharma-game
Pfizer, AstraZeneca, Sanofi And Mainz Biom...
05/16/2024 12:51:36

On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will...

johnson--johnson-to-acquire-proteologix-inc-to-lead-in-atopic-dermatitis-treatment-for-850m-cash-and-earnout-consideration
Johnson & Johnson to Acquire Proteologix, ...
05/16/2024 11:33:31

Johnson & Johnson (NYSE:JNJ) announced today that it has entered into a definitive agreement to acquire Proteologix, Inc., ...

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
05/15/2024 17:35:22

Core News & Articles
Kenvue Priced Secondary Offering Of 182.3M...
05/14/2024 23:17:46

johnson--johnsons-subsidiary-discontinues-some-megadyne-electrodes-for-pediatric-use
Johnson & Johnson's Subsidiary Discontinue...
05/13/2024 18:30:43

Johnson & Johnson's Megadyne Mega Soft Pediatric Patient Return Electrodes recalled due to patient burns. FDA's Cla...

Core News & Articles
Kenvue Announces Launch of Secondary Offer...
05/13/2024 10:48:08

Kenvue Inc. (NYSE:KVUE) ("Kenvue") announced today the launch of a secondary underwritten public offering (the "Off...

Core News & Articles
Kenvue Filed For Offering Of 182.3M Shares...
05/13/2024 10:43:37

-S-1

fda-says-megadyne-initiates-global-discontinuation-and-voluntary-recall-of-mega-soft-pediatric-patient-return-electrode
FDA Says Megadyne Initiates Global Discont...
05/10/2024 15:45:16

- Reuters

johnson--johnsons-taris-platform---goldman-sachs-outlines-potential-for-the-bladder-cancer-therapy
Johnson & Johnson's TARIS Platform - Goldm...
05/07/2024 18:31:50

Johnson & Johnson unveils promising TARIS platform data for bladder cancer treatment, highlighting ease of administration a...

Core News & Articles
Shockwave Medical Says Given The Proposed ...
05/06/2024 20:09:42

2024 Financial GuidanceGiven the proposed acquisition of Shockwave Medical by Johnson & Johnson (NYSE:JNJ), Shockwave Medic...

johnson--johnson-advances-its-two-bladder-cancer-studies-releases-latest-data
Johnson & Johnson Advances Its Two Bladder...
05/06/2024 18:10:36

Johnson & Johnson's results in treating bladder and prostate cancer. Learn about TAR-210's efficacy in high-risk NM...

comparing-johnson-amp-johnson-with-industry-competitors-in-pharmaceuticals-industry
Comparing Johnson & Johnson With Indus...
05/06/2024 15:00:34

on-may-5-2024-johnson--johnson-updated-results-from-multi-cohort-phase-1-study-of-the-safety-and-efficacy-tar-210-results-show-90-recurrence-free-survival-and-90-complete-response-in-patients-with-high-risk-and-intermediate-risk-non-muscle-invasive-bladder-cancer-respectively
On May 5, 2024, Johnson & Johnson Updated ...
05/06/2024 14:27:30

Updated results reinforce the potential of TAR-210 to transform treatment of non–muscle-invasive bladder cancer with fibroblast...

cantor-fitzgerald-reiterates-overweight-on-johnson--johnson-maintains-215-price-target
Cantor Fitzgerald Reiterates Overweight on...
05/06/2024 13:59:49

Cantor Fitzgerald analyst Louise Chen reiterates Johnson & Johnson (NYSE:JNJ) with a Overweight and maintains $215 price...

johnson--johnson-announces-phase-2-data-for-erleada-plus-androgen-deprivation-therapy-following-radical-prostatectomy-in-patients-with-high-risk-localized-prostate-cancer-show-100-biochemical-free-recurrence-rate-more-than-two-years-post-surgery-study-met-its-primary-endpoint-safety-profile-of-erleada-with-adt-was-consistent-with-previous-reports
Johnson & Johnson Announces Phase 2 Data F...
05/03/2024 16:23:19

Study highlights opportunity for treatment intensification in this population since approximately 50% of patients with high-ris...

johnson--johnson-says-tar-200-monotherapy-shows-greater-than-80-complete-response-rate-in-patients-with-high-risk-non-muscle-invasive-bladder-cancer-new-data-from-phase-2b-sunrise-1-study-show-rapid-achievement-of-complete-response-with-98-achieving-a-cr-within-12-weeks
Johnson & Johnson Says TAR-200 Monotherapy...
05/03/2024 15:20:51

- Reuters

nasdaq-sp-500-futures-rise-ahead-of-apple-earnings-why-this-analyst-thinks-no-cut-scenario-may-not-be-negative-for-market
Nasdaq, S&P 500 Futures Rise Ahead Of Appl...
05/02/2024 10:52:51

U.S. stocks look to push ahead on a positive path, now that the Federal Reserve’s rate decision is in the rearview mirror. Majo...

johnson--johnson-wants-to-deal-with-talc-lawsuit-overhang-proposes-65b-settlement-package
Johnson & Johnson Wants To Deal With Talc ...
05/01/2024 18:42:19

Johnson & Johnson announces $6.475 billion settlement for talc-related ovarian cancer lawsuits. Details on proposed resolut...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION